Search

Your search keyword '"Konstantopoulou I."' showing total 155 results

Search Constraints

Start Over You searched for: Author "Konstantopoulou I." Remove constraint Author: "Konstantopoulou I." Language english Remove constraint Language: english
155 results on '"Konstantopoulou I."'

Search Results

3. Article chek2 pathogenic variants in greek breast cancer patients: Evidence for strong associations with estrogen receptor positivity, overuse of risk-reducing procedures and population founder effects

5. Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses

6. Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses

7. Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes

8. Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses

9. BRCA1 and BRCA2 germline testing in Cretan isolates reveals novel and strong founder effects

10. Pathology of BRCA1- and BRCA2-associated Breast Cancers: Known and Less Known Connections

13. PALB2 c.2257C>T truncating variant is a Greek founder and is associated with high breast cancer risk

14. The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer

16. Characterization and prevalence of two novel CHEK2 large deletions in Greek breast cancer patients

17. Haplotype analysis reveals that the recurrent BRCA1 deletion of exons 23 and 24 is a Greek founder mutation

18. Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers

19. BRCA2 polymorphic stop codon K3326X and the risk of breast, prostate, and ovarian cancers

20. An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers

21. Assessing Associations between the AURKA-HMMR-TPX2-TUBG1 Functional Module and Breast Cancer Risk in BRCA1/2 Mutation Carriers

22. CHEK2 c.1100delC allele is rarely identified in Greek breast cancer cases

23. Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers

24. AlphaB-crystallin is a marker of aggressive breast cancer behavior but does not independently predict for patient outcome: A combined analysis of two randomized studies

25. DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in BRCA1 and BRCA2 Mutation Carriers

26. Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: Implications for genetic screening selection criteria: A Hellenic Cooperative Oncology Group Study

27. A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer

28. ENIGMA - Evidence-based Network for the Interpretation of Germline Mutant Alleles: An international initiative to evaluate risk and clinical significance associated with sequence variation in BRCA1 and BRCA2 genes

29. Common Breast Cancer Susceptibility Loci Are Associated with Triple-Negative Breast Cancer

30. Evaluation of the XRCC1 gene as a phenotypic modifier in BRCA1/2 mutation carriers. Results from the consortium of investigators of modifiers of BRCA1/BRCA2

31. Association of the Variants CASP8 D302H and CASP10 V410I with Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers

32. Contribution of BRCA1 germ-line mutations to breast cancer in Greece: a hospital-based study of 987 unselected breast cancer cases

33. Greek BRCA1 and BRCA2 mutation spectrum: Two BRCA1 mutations account for half the carriers found among high-risk breast/ovarian cancer patients

35. Growth index is independent of microvessel density in non-small-cell lung carcinomas

36. Germ line BRCA1 & BRCA2 mutations in Greek breast/ovarian cancer families: 5382insC is the most frequent mutation observed

37. The TP53 Arg72Pro and MDM2 309G>T polymorphisms are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers.

38. Contribution of BRCA1 germ-line mutations to breast cancer in Greece: a hospital-based study of 987 unselected breast cancer cases.

39. Insecticidal effects of essential oils. A study of the effects of essential oils extracted from eleven Greek aromatic plants on Drosophila auraria.

41. Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus

42. Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer

43. Germ line BRCA1 & BRCA2 mutations in Greek breast/ovarian cancer families: 5382insC is the most frequent mutation observed

44. Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers

45. Neoadjuvant Capecitabine Plus Temozolomide in Atypical Lung NETs.

46. Genetic Testing of Breast Cancer Patients with Very Early-Onset Breast Cancer (≤30 Years) Yields a High Rate of Germline Pathogenic Variants, Mainly in the BRCA1, TP53, and BRCA2 Genes.

47. Large-scale genome-wide association study of 398,238 women unveils seven novel loci associated with high-grade serous epithelial ovarian cancer risk.

48. ENIGMA CHEK2gether Project: A Comprehensive Study Identifies Functionally Impaired CHEK2 Germline Missense Variants Associated with Increased Breast Cancer Risk.

49. Ovarian cancer pathology characteristics as predictors of variant pathogenicity in BRCA1 and BRCA2.

50. Copy number variants as modifiers of breast cancer risk for BRCA1/BRCA2 pathogenic variant carriers.

Catalog

Books, media, physical & digital resources